GlassScriptPhysician profile
Joseph R Berardi
NPI 1497723688
$4,957.73
in general payments reported to CMS, 2019-2025
18 companies · $310 in 2025
The $310 reported for 2025 was less than what a typical Ophthalmology provider received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,062 · 2020: $510 · 2021: $731 · 2022: $912 · 2023: $464 · 2024: $969 · 2025: $310.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,743.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,743.35 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alcon Vision LLC | $1,226.32 | 2019-2025 | Rocklatan, Simbrinza, Clareon |
| Abbvie INC. | $894.34 | 2022-2025 | Durysta |
| Aerie Pharmaceuticals, INC. | $571.99 | 2019-2021 | |
| Allergan, INC. | $490.30 | 2019-2022 | |
| Bausch & Lomb Americas INC. | $430.59 | 2022-2025 | Vyzulta, Miebo, Xiidra |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $379.99 | 2019-2021 | |
| Sun Pharmaceutical Industries INC. | $277.29 | 2019-2024 | |
| Novartis Pharmaceuticals Corporation | $169.02 | 2019-2021 | |
| Oyster Point Pharma, INC. | $123.43 | 2022-2024 | Tyrvaya |
| Omeros Corporation | $119.86 | 2019 | |
| Tarsus Pharmaceuticals, INC. | $83.78 | 2024-2025 | Xdemvy |
| Ivantis, INC | $43.90 | 2020-2021 | |
| Kala Pharmaceuticals, INC. | $40.58 | 2019 | |
| Carl Zeiss Meditec, INC. | $36.11 | 2023 | |
| Shire North American Group INC | $21.73 | 2019 |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sight Sciences, INC. | $19.41 | 2023 | Sion Surgical Instrument |
| Spark Therapeutics, INC. | $16.71 | 2019 | |
| Horizon Therapeutics Plc | $12.38 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Joseph Berardi listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.